Skip to main content
NCBI home page
Clinical Cardiology logoLink to Clinical Cardiology
. 2006 Dec 5;26(7):305–311. doi: 10.1002/clc.4950260703

Modulating atherosclerosis through inhibition or blockade of angiotensin

Robert S Rosenson 1,✉
PMCID: PMC6654059  PMID: 12862295

Abstract

Angiotensin‐converting enzyme (ACE) inhibitors are well recognized for their benefits in treating hypertension and congestive heart failure and preventing postmyocardial infarction heart failure or left ventricular (LV) dysfunction. Recently, blockade of the angiotensin II type 1 (AT1) receptor was shown to reduce cardiovascular events in hypertensive subjects with LV hypertrophy. Several lines of evidence are now converging to show that ACE inhibitors may affect the atherosclerotic process itself. Emerging clinical data indicate that angiotensin‐receptor blockers (ARBs) may possibly modulate atherosclerosis as well. The antiatherogenic properties of ACE inhibitors and ARBs may derive from inhibition or blockade of angiotensin II, now recognized as an agent that increases oxidative stress. Angiotensin‐converting enzyme inhibition and angiotensin‐receptor blockade also increase endothelial nitric oxide formation, which improves endothelial function. In contrast to the effects of ARBs, the vascular effects of ACE inhibitors may, in part, be mediated by an increase in bradykinin. This article reviews some of the biologic mechanisms whereby ACE inhibitors and ARBs may modulate atherosclerosis.

Keywords: atherosclerosis, angiotensin‐converting enzyme inhibitors, angiotensin‐receptor blockers, oxidative stress, endothelial dysfunction, angiotensin II, bradykinin, nitric oxide

Full Text

The Full Text of this article is available as a PDF (50.1 KB).

References

  • 1. The CONSENSUS Trial Study Group : Effects of enalapril on mortality in severe congestive heart failure: Results of the Cooperative North Scandinavian Enalapril Survival Study (CONSENSUS). N Engl J Med 1987; 316:1429–1435 [DOI] [PubMed] [Google Scholar]
  • 2. The SOLVD Investigators : Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. N Engl J Med 1991; 325:293–302 [DOI] [PubMed] [Google Scholar]
  • 3. Yusuf S, Pepine CJ, Garces C, Pouleur H, Salem D, Kostis J, Benedict C, Rousseau M, Bourassa M, Pitt B: Effect of enalapril on myocardial infarction and unstable angina in patients with low ejection fractions (see comments). Lancet 1992; 340:1173–1178 [DOI] [PubMed] [Google Scholar]
  • 4. Pfeffer MA, Braunwald E, Moyé LA, Basta L, Brown EJ Jr, Cuddy TE, Davis BR, Geltman EM, Goldman S, Flaker GC, Klein M, Lamas GA, Packer M, Rouleau J, Rouleau JL, Rutherford J, Wertheimer JH, Hawkins CM, on behalf of the SAVE Investigators : Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction: Results of the Survival and Ventricular Enlargement trial. N Engl J Med 1992; 327:669–677 [DOI] [PubMed] [Google Scholar]
  • 5. The Acute Infarction Ramipril Efficacy (AIRE) Study Investigators : Effect of ramipril on mortality and morbidity of survivors of acute myocardial infarction with clinical evidence of heart failure. Lancet 1993; 342:821–828 [PubMed] [Google Scholar]
  • 6. Køber L, Torp‐Pedersen C, Carlsen JE, Bagger H, Eliasen P, Lyngborg K, Videbæk J, Cole DS, Auclert L, Pauly NC, Aliot E, Persson S, Camm AJ, for the Trandolapril Cardiac Evaluation (TRACE) study group : A clinical trial of the angiotensin‐converting enzyme inhibitor trandolapril in patients with left ventricular dysfunction after myocardial infarction (see comments). N Engl J Med 1995; 333:1670–1676 [DOI] [PubMed] [Google Scholar]
  • 7. Dahlof B, Devereux RB, Kjeldsen SE, Julius S, Beevers G, de Faire U, Fyhrquist F, Ibsen H, Kristiansson K, Lederballe‐Pedersen O, Lindholm LH, Nieminen MS, Omvik P, Oparil S, Wedel H, for the LIFE study group : Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): A randomised trial against atenolol. Lancet 2002; 359:995–1003 [DOI] [PubMed] [Google Scholar]
  • 8. Dzau VJ: Mechanism of protective effects of ACE inhibition on coronary artery disease. Eur Heart J 1998; 19(suppl J): J2–J6 [PubMed] [Google Scholar]
  • 9. Kunsch C, Medford RM: Oxidative stress as a regulator of gene expression in the vasculature. Circ Res 1999; 85:753–766 [DOI] [PubMed] [Google Scholar]
  • 10. The Heart Outcomes Prevention Evaluation Study Investigators : Effects of an angiotensin‐converting enzyme inhibitor, ramipril, on cardiovascular events in high‐risk patients. N Engl J Med 2000; 342:145–153 [DOI] [PubMed] [Google Scholar]
  • 11. Heart Outcomes Prevention Evaluation (HOPE) Study Investigators : Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: Results of the HOPE study and MICRO‐HOPE substudy. Lancet 2000; 355:253–259 [PubMed] [Google Scholar]
  • 12. Lonn EM, Yusuf S, Dzavik V, Doris CI, Yi Q, Smith S, Moore‐Cox A, Bosch J, Riley WA, Teo KK, for the SECURE Investigators : Effects of ramipril and vitamin E on atherosclerosis: The Study to Evaluate Carotid Ultrasound changes in patients treated with Ramipril and vitamin E (SECURE). Circulation 2001; 103:919–925 [DOI] [PubMed] [Google Scholar]
  • 13. Ross R: Atherosclerosis–an inflammatory disease. N Engl J Med 1999; 340:115–126 [DOI] [PubMed] [Google Scholar]
  • 14. Steinberg D, Parthasarathy S, Carew TE, Khoo JC, Witztum JL: Beyond cholesterol: Modifications of low‐density lipoprotein that increase its atherogenicity. N Engl J Med 1989; 320:915–924 [DOI] [PubMed] [Google Scholar]
  • 15. Alexander RW: Theodore Cooper Memorial Lecture. Hypertension and the pathogenesis of atherosclerosis: Oxidative stress and the mediation of arterial inflammatory response: A new perspective. Hypertension 1995; 25:155–161 [DOI] [PubMed] [Google Scholar]
  • 16. Griendling KK, Sorescu D, Ushio‐Fukai M: NAD(P)H oxidase: Role in cardiovascular biology and disease. Circ Res 2000; 86:494–501 [DOI] [PubMed] [Google Scholar]
  • 17. Griendling KK, Minieri CA, Ollerenshaw JD, Alexander RW: Angiotensin II stimulates NADH and NADPH oxidase activity in cultured vascular smooth muscle cells. Circ Res 1994; 74:1141–1148 [DOI] [PubMed] [Google Scholar]
  • 18. Jones SA, O'Donnell VB, Wood JD, Broughton JP, Hughes EJ, Jones OTG: Expression of phagocyte NADPH oxidase components in human endothelial cells. Am J Physiol 1996; 271:H1626–H1634 [DOI] [PubMed] [Google Scholar]
  • 19. De Keulenaer GW, Alexander RW, Ushio‐Fukai M, Ishizaka N, Griendling KK: Tumor necrosis factor a activates a p22phox‐based NADH oxidase in vascular smooth muscle. Biochem J 1998; 329:653–657 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 20. Mäkimattila S, Luoma JS, Yl´‐Herttuala S, Bergholm R, Utriainen T, Virkamäki A, Mäntysaari M, Summanen P, Yki‐Järvinen H: Autoantibodies against oxidized LDL and endothelium‐dependent vasodilation in insulin‐dependent diabetes mellitus. Atherosclerosis 1999; 147:115–122 [DOI] [PubMed] [Google Scholar]
  • 21. Warnholtz A, Nickenig G, Schulz E, Macharzina R, Bräsen JH, Skatchkov M, Heitzer T, Stasch JP, Griendling KK, Harrison DG, Böhm M, Meinertz T, Münzel T: Increased NADH‐oxidase‐mediated superoxide production in the early stages of atherosclerosis: Evidence for involvement of the renin‐angiotensin system. Circulation 1999; 99:2027–2033 [DOI] [PubMed] [Google Scholar]
  • 22. Kissner R, Nauser T, Bugnon P, Lye PG, Koppenol WH: Formation and properties of peroxynitrite as studied by laser flash photolysis, high‐pressure stopped‐flow technique, and pulse radiolysis. Chem Res Toxicol 1997; 10:1285–1292 [DOI] [PubMed] [Google Scholar]
  • 23. Beckman JS, Beckman TW, Chen J, Marshall PA, Freeman BA: Apparent hydroxyl radical production by peroxynitrite: Implications for endothelial injury from nitric oxide and superoxide. Proc Nat Acad Sci 1990; 87:1620–1624 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 24. Münzel T, Keaney JF Jr: Are ACE inhibitors a “magic bullet” against oxidative stress? Circulation 2001; 104:1571–1574 [DOI] [PubMed] [Google Scholar]
  • 25. Schächinger V, Britten MB, Zeiher AM: Prognostic impact of coronary vasodilator dysfunction on adverse long‐term outcome of coronary heart disease. Circulation 2000; 101:1899–1906 [DOI] [PubMed] [Google Scholar]
  • 26. Vaughan DE, Lazos SA, Tong K: Angiotensin II regulates the expression of plasminogen activator inhibitor‐1 in cultured endothelial cells: A potential link between the renin‐angiotensin system and thrombosis. J Clin Invest 1995; 95:995–1001 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 27. Ridker PM, Gaboury CL, Conlin PR, Seely EW, Williams GH, Vaughan DE: Stimulation of plasminogen activator inhibitor in vivo by infusion of angiotensin II: Evidence of potential interaction between the renin‐angiotensin system and fibrinolytic function. Circulation 1993; 87:1969–1973 [DOI] [PubMed] [Google Scholar]
  • 28. Farmer JA: Renin angiotensin system and ASCVD. Curr Opin Cardiol 2000; 15:141–150 [DOI] [PubMed] [Google Scholar]
  • 29. Jackson EK, Garrison JC: Renin and angiotensin In Goodman & Gilman's The Pharmacological Basis of Therapeutics, 9th ed, (Eds. Goodman LS, Limbird LE, Hardman JG.) p. 733–758. New York, N.Y.: McGraw‐Hill, 1996. [Google Scholar]
  • 30. Brown NJ, Vaughan DE: Angiotensin‐converting enzyme inhibitors. Circulation 1998; 97:1411–1420 [DOI] [PubMed] [Google Scholar]
  • 31. Gibbons GH, Pratt RE, Dzau VJ: Vascular smooth muscle cell hypertrophy vs. hyperplasia: Autocrine transforming growth factor‐β1 expression determines growth response to angiotensin II. J Clin Invest 1992; 90:456–461 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 32. Itoh H, Mukoyama M, Pratt RE, Gibbons GH, Dzau VJ: Multiple autocrine growth factors modulate vascular smooth muscle cell growth response to angiotensin II. J Clin Invest 1993; 91:2268–2274 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 33. Hernández‐Presa M, Bustos C, Ortego M, Tuñon J, Renedo G, Ruiz‐Ortega M, Egido J: Angiotensin‐converting enzyme inhibition prevents arterial nuclear factor‐KB activation, monocyte chemoattractant protein‐1 expression, and macrophage infiltration in a rabbit model of early accelerated atherosclerosis. Circulation 1997; 95:1532–1541 [DOI] [PubMed] [Google Scholar]
  • 34. Diet F, Pratt RE, Berry GJ, Momose N, Gibbons GH, Dzau VJ: Increased accumulation of tissue ACE in human atherosclerotic coronary artery disease. Circulation 1996; 94:2756–2767 [DOI] [PubMed] [Google Scholar]
  • 35. Curzen NP, Fox KM: Do ACE inhibitors modulate atherosclerosis? Eur Heart J 1997; 18:1530–1535 [DOI] [PubMed] [Google Scholar]
  • 36. Vanhoutte PM, Boulanger CM, Illiano SC, Nagao T, Vidal M, Mombouli J‐V: Endothelium‐dependent effects of converting‐enzyme inhibitors. J Car‐diovasc Pharmacol 1993; 22(suppl 5): S10–S16 [DOI] [PubMed] [Google Scholar]
  • 37. Benzing T, Fleming I, Blaukat A, Müller‐Esterl W, Busse R: Angiotensin‐converting enzyme inhibitor ramiprilat interferes with the sequestration of the B2 kinin receptor within the plasma membrane of native endothelial cells. Circulation 1999; 99:2034–2040 [DOI] [PubMed] [Google Scholar]
  • 38. Li DY, Zhang YC, Philips MI, Sawamura T, Mehta JL: Upregulation of endothelial receptor for oxidized low‐density lipoprotein (LOX‐1) in cultured human coronary artery endothelial cells by angiotensin II type 1 receptor activation. Circ Res 1999; 84:1043–1049 [DOI] [PubMed] [Google Scholar]
  • 39. Cominacini L, Pasini AF, Garbin U, Davoli A, Tosetti ML, Campagnola M, Rigoni A, Pastorino AM, Lo Cascio V, Sawamura T: Oxidized low‐density lipoprotein (ox‐LDL) binding to ox‐LDL receptor‐1 in endothelial cells induces the activation of NF‐κB through an increased production of intracellular reactive oxygen species. J Biol Chem 2000; 275:12633–12638 [DOI] [PubMed] [Google Scholar]
  • 40. Hope S, Brecher P, Chobanian AV: Comparison of the effects of AT1 receptor blockade and angiotensin‐converting enzyme inhibition on atherosclerosis. Am J Hypertens 1999; 12:28–34 [DOI] [PubMed] [Google Scholar]
  • 41. Strawn WB, Chappell MC, Dean RH, Kivlighn S, Ferrario CM: Inhibition of early atherogenesis by losartan in monkeys with diet‐induced hypercholesterolemia. Circulation 2000; 101:1586–1593 [DOI] [PubMed] [Google Scholar]
  • 42. Bosch J, Yusuf S, Pogue J, Sleight P, Lonn E, Rangoonwala B, Davies R, Ostergren J, Probstfield J, on behalf of the HOPE Investigators : Use of ramipril in preventing stroke: Double blind randomised trial. Br Med J 2002; 324:699–703 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 43. Pitt B: The anti‐ischemic potential of angiotensin‐converting enzyme inhibition: Insights from the Heart Outcomes Prevention Evaluation trial. Clin Cardiol 2000; 23(suppl 4): IV‐9–IV‐14 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 44. Cashin‐Hemphill L, Holmvang G, Chan RC, Pitt B, Dinsmore RE, Lees RS, for the QUIET Investigators : Angiotensin‐converting enzyme inhibition as antiatherosclerotic therapy: No answer yet. Am J Cardiol 1999; 83:43–47 [DOI] [PubMed] [Google Scholar]
  • 45. Teo KK, Burton JR, Buller CE, Plante S, Catellier D, Tymchak W, Dzavik V, Taylor D, Yokoyama S, Montague TJ, for the SCAT Investigators : Long‐term effects of cholesterol lowering and angiotensin‐converting enzyme inhibition on coronary atherosclerosis: The Simvastatin/Enalapril Coronary Atherosclerosis Trial (SCAT). Circulation 2000; 102:1748–1754 [DOI] [PubMed] [Google Scholar]
  • 46. Meune C, Mahe I, Mourad JJ, Simoneau G, Knellwolf AL, Bergmann JF, Caulin C: Interaction between angiotensin‐converting enzyme inhibitors and aspirin: A review. Eur J Clin Pharmacol 2000; 56:609–620 [DOI] [PubMed] [Google Scholar]
  • 47. Cleland JGF, John J, Houghton T: Does aspirin attenuate the effect of angio‐tensin‐converting inhibitors in hypertension or heart failure? Curr Opin Nephrol Hypertens 2001; 10:625–631 [DOI] [PubMed] [Google Scholar]
  • 48. Davie AP, McMurray JJV: Effect of aspirin on vasodilation to bradykinin and substance P in patients with heart failure treated with ACE inhibitor. Br J Clin Pharmacol 2002; 53:37–42 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 49. Latini R, Santoro E, Masson S, Tavazzi L, Maggioni AP, Franzosi MG, Barlera S, Calvillo L, Salio M, Staszewsky L, Labarta V, Tognoni G, for the GISSI‐3 Investigators : Aspirin does not interact with ACE inhibitors when both are given early after acute myocardial infarction: Results of the GISSI‐3 Trial. Heart Dis 2000; 2:183–190 [PubMed] [Google Scholar]
  • 50. Kennedy HL, Rosenson RS: Physicians' interpretation of “class effects”: A need for thoughtful re‐evaluation. J Am Coll Cardiol 2002; 40:19–26 [DOI] [PubMed] [Google Scholar]
  • 51. Lindholm LH, Ibsen H, Dahlof B, Devereux RB, Beevers G, de Faire U, Fyhrquist F, Julius S, Kjeldsen SE, Kristiansson K, Lederballe‐Pedersen O, Nieminen MS, Omvik P, Oparil S, Wedel H, Aurup P, Edelman J, Snapinn S, for the LIFE study group : Cardiovascular morbidity and mortality in patients with diabetes in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): A randomised trial against atenolol. Lancet 2002; 359:1004–1010 [DOI] [PubMed] [Google Scholar]
  • 52. Ferdinand K, Arora R, Douglas J, Gavin J, Jamerson K, Saunders E, Taylor M, Watson K, Wright JT Jr: Hypertension and cardiovascular risk reduction in African Americans: A roundtable discussion. J Natl Med Assoc 2002; 94 (suppl 1): 1S–26S. [PMC free article] [PubMed] [Google Scholar]
  • 53. Dickstein K, Kjekshus J and the OPTIMAAL Steering Committee, for the OPTIMAAL Study Group : Effects of losartan and captopril on mortality and morbidity in high‐risk patients after acute myocardial infarction: The OPTIMAAL randomised trial. Lancet 2002; 360:752–760 [DOI] [PubMed] [Google Scholar]
  • 54. Lonn EM, Yusuf S, Jha P, Montague TJ, Teo KK, Benedict CR, Pitt B: Emerging role of angiotensin‐converting enzyme inhibitors in cardiac and vascular protection. Circulation 1994; 90:2056–2069 [DOI] [PubMed] [Google Scholar]

Articles from Clinical Cardiology are provided here courtesy of Wiley

RESOURCES